Drug intelligence / Profile preview

MAb35

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MAb35 is a murine monoclonal antibody directed against Carcinoembryonic Antigen (CEA). It has been investigated as a radioimmunoconjugate for radioimmunotherapy (RIT) of colorectal carcinoma. Studies have explored its labeling with radioisotopes such as Copper-67 (67Cu) and Iodine-125 (125I) to target colorectal tumors. The 67Cu-labeled MAb35 demonstrated more favorable tumor-to-blood ratios compared to its 125I-labeled counterpart, suggesting its potential for treating small tumor deposits in colorectal carcinoma patients, possibly as a component of multimodality adjuvant treatment.

Targets

CHRNA1 (nAChR α1 subunit)

Beyond the preview

Go deeper on MAb35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb35.

Explore the full profile